<DOC>
	<DOCNO>NCT00534638</DOCNO>
	<brief_summary>Genital infection oncogenic human papillomaviruses ( HPV ) common men woman . The important disease associate oncogenic HPV infection cervical cancer , currently second lead cause cancer-related death among woman globally . The current study design evaluate overall impact HPV immunization adolescent 12-15 year age . This protocol post update follow protocol amendment 09 , 24 March 2014 . The section impact secondary objective , endpoint , final analysis .</brief_summary>
	<brief_title>Effectiveness , Safety Immunogenicity GSK Biologicals ' HPV Vaccine GSK580299 ( Cervarix TM ) Administered Healthy Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Study participant investigator delegate believe and/or parents/legally acceptable representative comply requirement protocol ( e.g . completion diary card , return followup visit ) enrol study . A male female , include , 12 15 year age time first vaccination . A write informed assent must obtain study participant prior enrolment . In addition , write informed consent must obtain study participant ' parent legally acceptable representative . Note : As accord Finnish law legal age consent 15 year , write informed consent form obtain study participant age 15 year old parent ( ) /legally acceptable representative ( ) receive letter inform child participation study . Healthy male female study participant establish medical history enter study . If need , historydirected clinical examination perform investigator delegate ( e.g . study nurse ) . Study participant must pregnant . Absence pregnancy verify ( e.g . urine pregnancy test ) per investigator 's delegate 's clinical judgement . If study participant female , must nonchildbearing potential , i.e . abstinent , current tubal ligation , hysterectomy , ovariectomy postmenopausal premenarcheal , childbearing potential , must use adequate contraception 30 day prior vaccination continue 2 month completion vaccination series . Previous vaccination HPV Hepatitis B virus . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e . Oral temperature &lt; 37.5°C ( 99.5°F ) / Axillary temperature &lt; 37.5°C ( 99.5°F ) / Rectal temperature &lt; 38°C ( 100.4°F ) . ) Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HPV vaccine</keyword>
	<keyword>Healthy adolescent</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Cervarix</keyword>
</DOC>